Basking Biosciences Inc.
Primary industry: Therapeutics, Drug Delivery & Biotechnology
License fiscal year: 2021
Ohio State primary inventor(s): Shahid Nimjee
College: Medicine
Department: Neurological Surgery
baskingbiosciences.com
Description: Ischemic stroke, a condition where a clot blocks blood flow to the brain, affects approximately 700,000 people annually in the U.S. Ischemic strokes result 140,000 deaths each year and are a leading cause of long-term disability. Rapid restoration of blood flow to the brain is the only medical intervention proven to improve outcomes but only approximately 15-20% of patients qualify for either of the two FDA approved treatments. Basking Biosciences is developing a drug to dissolve the clot and a matched reversal agent to neutralize the drug if a patient shows signs of bleeding. Bleeding risk has limited the usage of the current FDA approved therapy in ischemic stroke patients. Basking’s reversible therapy has the potential to significantly expand the number of patients who can benefit from early therapy to restore blood flow to the brain.